Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In


Molecularly Targeted Therapy for Malignant Brain Tumors

Neuro−oncology is focusing on the uses of molecularly targeted agents in the adjuvant setting.
CME credit is no longer available for this conference.

Course Authors

Nicole A. Shonka, M.D., and Mark R. Gilbert, M.D.

Dr Shonka is a Fellow and Dr. Gilbert is the Deputy Chair and Professor, the Department of Neuro-Oncology, the University of Texas M.D. Anderson Cancer Center, Houston, TX.

Within the past 12 months, Dr. Shonka reports no commercial conflicts of interest, while Dr. Gilbert has received grant/research support from Genentech and Schering-Plough, and been a consultant to Genentech, Pfizer and Schering-Plough.

Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Highlight pathways important in gliomagenesis

  • Discuss the current use of molecularly targeted agents for gliomas, as well as efficacy and adverse effects of treatment

  • Discuss the ongoing research using targeted agents in the treatment of gliomas.



The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.


Please click below to accept the terms of this CME activity

Courses You Might Like


Estimated Time: 6 Hours

Emerging Treatments In Acute Myeloid Leukemia (AML)

Several investigational agents offer hope to patients with AML.
Authors: Mary-Elizabeth M. Percival, M.D., M.S. and Roland B. Walter, M.D., Ph.D., M.S.
Estimated Time: 1 Hour

Unexplained Bleeding in Hospitalized Patients

While some disorders are more readily apparent than others, not all bleeding is straightforward or has a readily identifiable cause.
Authors: Meera B. Chitlur, M.D.
Estimated Time: 1 Hour

Lung Cancer Chemoprevention

Despite advances in lung cancer chemotherapy, there is a pressing need for effective lung cancer chemoprevention beyond smoking cessation.
Authors: Robert L. Keith, M.D.
Estimated Time: 1 Hour

Anti-EGFR Therapy: Incidence, Pathology and Management of Associated Side Effects

This month, Sunil Babu, M.D., Michael Liu, M.D., and Robert G. Lerner, M.D., discuss

tissue including the epidermis, sweat gland apparatus and the hair follicle epithelium. , , The cutaneous reactions to EGFR inhibitors include follicular eruptions, generalized xerosis, pruritis, hyperpigmentation, panniculitis, paronychia, alopecia, trichomegaly, fine brittle hair, ocular irritation and vaginal dryness (Table 2). Current data suggest that skin eruption in patients taking
Authors: Sunil Babu, M.D., Michael Liu, M.D., and Robert G. Lerner, M.D.
Estimated Time: 1 Hour